FGFR2 and neoplasm: From this point of view, FGFR tyrosine kinase inhibitors should be more effective than ICIs if the tumors carry FGFR2 alterations because tumors with alterations in the FGFR2 genes generally showed a “non-inflamed” tumor phenotype [8].